IDEAS home Printed from https://ideas.repec.org/a/spr/drugsa/v46y2023i10d10.1007_s40264-023-01341-0.html
   My bibliography  Save this article

Duration of Effectiveness Evaluation of Additional Risk Minimisation Measures for Centrally Authorised Medicinal Products in the EU Between 2012 and 2021

Author

Listed:
  • Sharon C. M. Essink

    (Utrecht University
    Medicines Evaluation Board)

  • Inge M. Zomerdijk

    (Medicines Evaluation Board)

  • Sabine M. J. M. Straus

    (Medicines Evaluation Board
    Erasmus Medical Center)

  • Helga Gardarsdottir

    (Utrecht University
    University Medical Center Utrecht
    University of Iceland)

  • Marie L. Bruin

    (Utrecht University)

Abstract

Introduction In studies evaluating the effectiveness of additional risk minimisation measures (aRMMs), the need for speed must be properly balanced with the quality of the study. We assessed the duration of aRMM effectiveness evaluations, using additional pharmacovigilance activities, for centrally authorised medicinal products in the European Union. Methods We established a cohort of medicinal products with aRMMs at marketing authorisation (MA) that were centrally authorised from July 2012–December 2021 using the European Public Assessment Reports. Evaluation studies were identified from the Risk Management Plans at the time of MA. Subsequently, we retrieved protocols, final study reports, Pharmacovigilance Risk Assessment Committee (PRAC) assessment reports, and PRAC minutes. We calculated the probability of completing an effectiveness evaluation within 60 months after MA using time-to-event analyses. Besides, we compared the planned final report with the actual final report date. Results We identified 134 medicinal products authorised with aRMMs, of which almost half (n = 63, 47.0%) had an effectiveness evaluation study. The probability of an evaluation for a medicinal product being completed within 60 months after MA was 20.7% (95% CI 6.8–32.6). Regarding study design, the probability of completing a study was higher for cross-sectional studies when compared to cohort studies (p = 0.002). Moreover, 81.0% of studies were delayed when compared to their planned final report date. Conclusion The probability of completing an aRMM effectiveness evaluation at time for renewal of the MA was only one in five. Furthermore, estimates of the duration of studies around MA are too optimistic, with the majority being delayed.

Suggested Citation

  • Sharon C. M. Essink & Inge M. Zomerdijk & Sabine M. J. M. Straus & Helga Gardarsdottir & Marie L. Bruin, 2023. "Duration of Effectiveness Evaluation of Additional Risk Minimisation Measures for Centrally Authorised Medicinal Products in the EU Between 2012 and 2021," Drug Safety, Springer, vol. 46(10), pages 1007-1020, October.
    • Handle: RePEc:spr:drugsa:v:46:y:2023:i:10:d:10.1007_s40264-023-01341-0
    DOI: 10.1007/s40264-023-01341-0
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40264-023-01341-0
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40264-023-01341-0?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Reynold D. C. Francisca & Emna Baba & Christina E. Hoeve & Inge M. Zomerdijk & Miriam C. J. M. Sturkenboom & Sabine M. J. M. Straus, 2021. "Introduction or Discontinuation of Additional Risk Minimisation Measures During the Life Cycle of Medicines in Europe," Drug Safety, Springer, vol. 44(1), pages 63-72, January.
    2. Christina E. Hoeve & Reynold D. C. Francisca & Inge Zomerdijk & Miriam C. J. M. Sturkenboom & Sabine M. J. M. Straus, 2020. "Description of the Risk Management of Medication Errors for Centrally Authorised Products in the European Union," Drug Safety, Springer, vol. 43(1), pages 45-55, January.
    3. Rania Mouchantaf & Doris Auth & Yola Moride & June Raine & Soon Young Han & Meredith Y. Smith, 2021. "Risk Management for the 21st Century: Current Status and Future Needs," Drug Safety, Springer, vol. 44(4), pages 409-419, April.
    4. Giampiero Mazzaglia & Sabine M. J. Straus & Peter Arlett & Daniela Silva & Heidi Janssen & June Raine & Enrica Alteri, 2018. "Study Design and Evaluation of Risk Minimization Measures: A Review of Studies Submitted to the European Medicines Agency for Cardiovascular, Endocrinology, and Metabolic Drugs," Drug Safety, Springer, vol. 41(2), pages 191-202, February.
    5. Sonja Kallio & Tiina Eskola & Marika Pohjanoksa-Mäntylä & Marja Airaksinen, 2020. "Medication Risk Management in Routine Dispensing in Community Pharmacies," IJERPH, MDPI, vol. 17(21), pages 1-12, November.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Camille Goyer & Genaro Castillon & Yola Moride, 2022. "Implementation of Interventions and Policies on Opioids and Awareness of Opioid-Related Harms in Canada: A Multistage Mixed Methods Descriptive Study," IJERPH, MDPI, vol. 19(9), pages 1-12, April.
    2. Andrea M. Russell & Elaine H. Morrato & Rebecca M. Lovett & Meredith Y. Smith, 2020. "Quality of Reporting on the Evaluation of Risk Minimization Programs: A Systematic Review," Drug Safety, Springer, vol. 43(5), pages 427-446, May.
    3. Taina Oravainen & Marja Airaksinen & Kaija Hannula & Kirsi Kvarnström, 2021. "How Physicians Renew Electronic Prescriptions in Primary Care: Therapeutic Decision or Technical Task?," IJERPH, MDPI, vol. 18(20), pages 1-14, October.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:46:y:2023:i:10:d:10.1007_s40264-023-01341-0. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.